End-tidal carbon dioxide and amplitude spectral area as non-invasive markers of coronary perfusion pressure

Information

  • Patent Grant
  • 10835175
  • Patent Number
    10,835,175
  • Date Filed
    Wednesday, March 21, 2018
    6 years ago
  • Date Issued
    Tuesday, November 17, 2020
    4 years ago
Abstract
End-tidal carbon dioxide (ETCO2) measurements may be used alone as a guide to determine when to defibrillate an individual. Alternatively, ETCO2 measurements may be used in combination with amplitude spectral area measurements as a guide to determine when to defibrillate an individual.
Description
SUMMARY

Amplitude Spectrum Area (AMSA) values during ventricular fibrillation (VF) correlate with myocardial energy stores and predict defibrillation success. AMSA calculations however require particular hardware and/or software, and are clinically not used to determine an optimal time to deliver a defibrillation shock. By contrast, end tidal CO2 (ETCO2) values provide a non-invasive assessment of circulation during cardiopulmonary resuscitation (CPR). Accordingly, it is contemplated that ETCO2 measurements, alone or in combination with AMSA, values may be utilized as a non-invasive means to determine an optimal time to deliver defibrillation during cardiac arrest and CPR. This is supported by acquired data that demonstrates a positive correlation between AMSA and ETCO2, as discussed throughout. In particular, it has been demonstrated that AMSA and ETCO2 correlate with each other and can be used to correlate with myocardial perfusion. This correlation may be used as a way to provide additional support for more widespread use of ETCO2 to help guide defibrillation therapy.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 shows blood flow during multiple different CPR methods (porcine VF model).



FIG. 2 shows details of a model used to demonstrate AMSA and ETCO2 correlation.



FIG. 3 shows parameter results using three different CPR techniques.



FIG. 4 shows a representative spectrum from a porcine model during each of three methods of CPR.



FIG. 5 demonstrates a correlation between AMSA and ETCO2.



FIG. 6 shows results of Bland-Altman analysis indicating the 95% limits of agreement between AMSA and ETCO2 ranged from −21.4 to −33.5.



FIG. 7 shows an example treatment system in accordance with the present disclosure.



FIG. 8 shows an example computing system or device.





DETAILED DESCRIPTION

Using multiple CPR methods to generate several different levels of coronary perfusion and cerebral perfusion, a correlation between ETCO2 and AMSA values is identified. The data establishes a firm correlation between ETCO2 and AMSA, and demonstrates that ETCO2 may be useful as an independent indicator as to when to deliver a defibrillation shock. In particular, in one example embodiment, ETCO2 measurements may be used alone as a guide to determine when to defibrillate an individual. In another example embodiment, ETCO2 measurements may be used in combination with AMSA values as a guide to determine when to defibrillate an individual. Although not so limited, an appreciation of the various aspects of the disclosure may be acquired from the following description in connection with the drawings.


The International Consensus on Cardiopulmonary Resuscitation 2010 recommends delivering a defibrillation shock every two minutes during treatment of cardiac arrest. The magnitude of the electrical energy of the delivered shock, however, has been demonstrated to be related to the severity of post-resuscitation global myocardial dysfunction. Additionally, interruptions in precordial compressions have been determined to reduce coronary perfusion pressures (CoPP) which may compromise the success of the shocks, especially after prolonged cardiac arrest. To limit the number of unnecessary shocks and interruptions in precordial compressions, VF waveform analysis has been established to predict the success of defibrillation at any given time. Several different analysis methods have been developed and the most efficient of these methodologies is to examine the AMSA values. The technique to determine AMSA values however is generally not instantaneous due to the need to sequentially sample and filter a large amount of electrocardiographic data and then perform multiple calculations. As such, AMSA is not recommended for routine use in the guideline for defibrillation management in adult cardiac arrest in the clinical setting in or out-of-hospital.


Establishing an accurate and rapid method to predict the success of defibrillation may have a substantial impact on the survival outcome of a patient. Several studies have demonstrated ETCO2 values parallel changes in cardiac output, CoPP and myocardial perfusion while AMSA calculations are associated with CoPP. Since both AMSA and ETCO2 are indicated to correlate with CoPP during cardiac arrest, one aspect of the disclosure is that ETCO2 would reflect AMSA values during VF and CPR based upon the differences in flow as a consequence of the different methods of CPR. This association may provide a simple noninvasive means for medical practitioners to determine the optimal time for defibrillation. The present disclosure demonstrates a correlation between the parameters of ETCO2 and AMSA. Specifically, three CPR methods, each generating a different level of perfusion, are utilized to establish the association between ETCO2 and AMSA.


For example, FIG. 1 shows blood flow during CPR in the left ventricle and brain (porcine VF model) using a standard CPR procedure (STD CPR), a standard CPR procedure using an impedance threshold device (STD CPR+ITD), and an active compression-decompression CPR procedure using an impedance threshold device (ACD CPR+ITD). As shown in FIG. 1, magnitude of blood flow increases in order of: STD CPR (leftmost bar); STD CPR+ITD (middle bar); and ACD CPR+ITD (rightmost bar).



FIG. 2 shows detail of a swine model utilized to establish the association between ETCO2 and AMSA. Twelve female farm pigs (32±1 kg) pigs (domestic crossbreed) were fasted overnight. They were sedated with 10 ml (100 mg/ml) of intramuscular ketamine HCl (Ketaset, Fort Dodge Animal Health, Fort Dodge, Iowa). An intravenous bolus of propofol (PropoFlo, Abbott Laboratories, North Chicago, Ill.) (2-3 mg/kg) was given via a lateral ear vein and then infused at a rate of 160-200 .mu.g/kg/min for the remainder of the preparatory phase. The animals were intubated with a 7.5 mm cuffed French endotracheal tube inflated to prevent air leaks. Positive pressure, volume control ventilation with a tidal volume of 10 ml/kg and room air was delivered with a NarkoMed 4A (North American Drager) ventilator. The respiratory rate was adjusted (average 12±2 bpm) to keep oxygen saturation above 96% and ETCO2 between 38-42 mmHg. While in a ventral recumbent position, an intracranial bolt was inserted into the animal's parietal lobe to measure intracranial pressure using a 3.5 French micromanometer pressure transducer (Miko-Tip Transducer, Millar Instruments, Inc., Houston, Tex.). The animals were then placed supine. The left femoral artery and left external jugular vein were cannulated using a modified Seldinger percutaneous technique. Central aortic blood pressures were measured continuously via a micromanometer-tipped Millar catheter placed in the chest cavity at the level of origin of the thoracic descending aorta. Central venous blood pressures were measured via a micromanometer-tipped Millar catheter placed in the superior vena cava, approximately 2 cm above the right atrium. Right atrial pressures were maintained between 5-7 mmHg during the preparatory phase. Carotid artery blood flows were measured using a bidirectional Doppler flow probe attached to the internal carotid artery (Transonic Systems, Ithaca, N.Y.). Surface ECG was also monitored continuously. A thermometer was placed in the rectum and body temperature maintained with a heating blanket between 37.0.degree. C. and 38.0.degree. C. during pre-study and post-ROSC phases. All data were or was digitized using a computer data analysis program (BIOPAC MP 150, BIOPAC Systems Inc., Calif.). ETCO2, tidal volume, and arterial oxygen saturation were recorded with a CO2SMO Plus (Novametrix Medical Systems, Wallingford, Conn.).


Following preparation, the animals were positioned for CPR and pre-arrest hemodynamic variables were measured. Ventricular fibrillation was induced in the anesthetized animal with application of a 50 Hz, 7.5 V AC electrical current through an electrophysiology catheter to the endocardial surface of the right ventricle. Propofol anesthesia was decreased to a rate of 100 .mu.g/kg/min and remained at this level during CPR. After 6 minutes of untreated cardiac arrest, mechanical CPR via a pneumatic piston attached to a compression pad was initiated. Chest compressions were performed with a rate of 100/min and a depth of 25% of the anteroposterior diameter as previously described. All animals were ventilated during CPR with supplemental oxygen (2 LPM) with a bag-valve resuscitator at a compression to ventilation ratio of 10:1 and a tidal volume of 10 ml/kg. As shown in FIG. 2, CPR was performed for a total of 9 minutes; 3 minutes of STD CPR, 3 minutes of STD CPR+impedance threshold device (ITD) (ResQPOD, Advanced Circulatory Systems Inc., Roseville, Minn., USA), and 3 minutes of active compression decompression (ACD) CPR+ITD. The transition from one method of CPR to the next was made in an uninterrupted manner. ACD CPR was performed using a suction cup attached to the pneumatic piston as previously described. After the 9 minutes of CPR, epinephrine (40 .mu.g/Kg) was administered intravenously and 1 minute later the pigs were defibrillated with up to 3 additional sequential 200 Joule transthoracic biphasic shocks. Following successful resuscitation and one hour of observation, the animal was given a bolus of propofol (100 mg) and euthanized with a bolus intravenous injection of 10M KCl (30 mg/Kg).


As part of data analysis, the electrocardiographic (ECG) signal was sampled at 300 Hz and stored in 1.6 second increments such that each 4 second wavelet was processed at intervals of 1.6 seconds. The ECG signal was filtered between 3 and 30 Hz to minimize low frequency artifacts produced by precordial compression and to exclude the electrical interference of ambient noise at frequencies greater than 48 Hz. Analog ECG signals were digitized and converted from a time domain to a frequency domain by fast Fourier transformation via a computer data analysis program (BIOPAC). Utilizing MATLAB 5.1 software (Mathworks Inc., Natick, Mass.), the sum of individual amplitudes and frequencies resulted in the amplitude spectrum area (i.e., AMSA). Power spectrums for the VF waveform were generated the same way.


The mean AMSA for each pig for each intervention was used for the analysis. The mean values for all hemodynamic parameters extracted from multiple 4 second intervals obtained contemporaneously with the AMSA data were measured and used for future analysis. All values with a non-normal distribution are expressed as Median (25:75 percentiles). A Friedman statistical test was conducted to analyze ETCO2, AMSA, the calculated coronary and cerebral perfusion pressure, aortic systolic, diastolic and mean pressure, right atrial pressure and intracranial pressure during the three CPR methods. Coronary perfusion pressures were determined by the difference between the diastolic aortic pressure and diastolic right atrial pressure during each CPR intervention. Cerebral perfusion pressures were determined by taking the difference between the aortic pressure and the intracranial pressure. Spearman correlation and Friedman tests were used to analyze the correlation between the different hemodynamic parameters. A Bland and Altman assessment was used to compare ETCO2 and AMSA values with a range of agreement defined as mean bias±1.96 SD. P values of <0.05 were considered statistically significant. Statistical analyses were performed with SPSS® Statistics 17.0 (IBM Corporation, Somers, N.Y., USA).


In review of results, it was found that there were significant differences in the ETCO2, AMSA, coronary perfusion pressure, cerebral perfusion pressure, systolic aortic pressure, mean aortic pressure, mean right atrial pressure and mean intracranial pressure based upon the method of CPR used. The key perfusion parameters were lowest with STD CPR, increased with STD CPR+ITD, and were highest with ACD CPR+ITD, as shown in Table 1:



















TABLE 1










Ao
RA
ICP






ETCO2
AMSA
Ao sys
Ao dia
mean
mean
mean
CePP
CoPP
CBF







STD
5.7
31.1
30.7
9.5
20.2
12.6
18.3
2.8
8.4
25


CPR
(4.5;
(26.9;
(28.3;
(8.4;
(18.2;
(11.4;
(14.8;
(1.4;
(6.1;
(14;



7.9)*
39.4)*
35.2)*
12.1)
22.4)*
15.7)*
22)*
8.1)*
10)*
36)


STD
15.2
39.7
37.7
10.5
22.9
15.5
19.6
5.7
10.6
24


CPR +
(13.9;
(29.9;
(33;
(8.9;
(22;
(13.4;
(16.2;
(3.2;
(7.9;
(14;


ITD
18.4)
45.8)
64.7)
19.4)
39.9)
27.5)
23.7)
14.8)
13.3)
29)


ACD
20.5
45.5
41.9
11.5
25.9
16.6
18.4
7.6
13.3
27


CPR +
(16.5;
(31.5;
(37;
(7.6;
(23.7;
(14.1;
(15.2;
(4.9;
(7.9;
(19;


LID
21.5)
50.8)
59.9)
18)
34.1)
22.3)
22.9)
17)
19.7)
45)





Median (25; 75 percentile); hemodynamic parameter using the three different cardiopulmonary resuscitation techniques.


Ao sys: systolic aortic pressure;


Ao dia: diastolic aortic pressure;


Ao mean: mean aortic pressure;


RA mean: mean right atrial pressure;


ICP mean: mean intracranial pressure;


CePP: cerebral perfusion pressure;


CoPP: Coronary perfusion pressure;


ETCO2: end tidal CO2 (mmHg);


AMSA: amplitude spectral area (mV-Hz);


CBF: Mean carotid blood flow (ml/min);


*p = 0.001 STD CPR < STD CPR + ITD < ACD CPR + ITD (Friedman statistical test).







The data of Table 1 is shown graphically in FIG. 3. STD CPR (leftmost bar); STD CPR+ITD (middle bar); and ACD CPR+ITD (rightmost bar).


The power spectrum for the VF waveform also changed significantly based upon the method of CPR. FIG. 4 shows a representative spectrum from one pig during each of the 3 methods of CPR, STD CPR (frontmost curve or trend); STD CPR+ITD (middle curve or trend); and ACD CPR+ITD (rearmost curve or trend). There was a pronounced increase in the high frequency signal in this representative study and when the respective values for all animals were averaged.


Further analysis demonstrated a correlation between AMSA and ETCO2 (r=0.374, p=0.025) and a correlation between AMSA and key hemodynamic parameters (coronary perfusion pressure, cerebral perfusion pressure, aortic systolic, diastolic and mean pressure) (p<0.05), as shown in Table 2:
















TABLE 2







Ao
Ao
Ao






AMSA
sys
dia
mean
CePP
CoPP
CBF






















ETCO2
0.374*
0.709*
0.315
0.723*
0.526*
0.340*
0.295



0.025
<0.001
0.061
<0.001
0.001
0.043
0.08


AMSA

0.541*
0.487*
0.612*
0.217
0.185
0.639*




0.001
0.003
<0.001
0.203
0.281
<0.001


Ao sys


0.611*
0.953*
0.825*
0.514*
0.567*





<0.001
<0.001
<0.001
0.001
<0.001


Ao dia



0.709*
0.499*
0.514*
0.411*






<0.001
0.002
0.001
0.006


Ao Mean




0.77*
0.575*
0.597*







<0.001
<0.001
<0.001


CePP





0.503*
0.373*








0.002
<0.001





Ao Ao Ao AMSA sys dia mean CePP CoPP CBF ETCO2 0.374* 0.709* 0.315 0.723* 0.526* 0.340* 0.295 0.025 <0.001 0.061 <0.001 0.001 0.08 AMSA 0.541* 0.487* 0.612* 0.217 0.185 0.639* 0.001 0.003 <0.001 0.203 0.281 <0.001 Ao 00.611* 0.953* 0.825* 0.514* 0.567* sys <0.001 <0.001 <0.001 0.001 <0.001 Ao 0.709* 0.499* 0.514* 0.411* dia <0.001 0.002 0.001 0.006 Ao 0.77* 0.575* 0.597* mean <0.001 <0.001 <0.001 CePP 0.503* 0.373* 0.002 <0.001


Correlation between the different hemodynamic parameter, rs and p, *correlation is significant.


Ao sys: systolic aortic pressure;


Ao dia: diastolic aortic pressure;


Ao mean: mean aortic pressure;


RA mean: mean right atrial pressure;


ICP mean: mean intracranial pressure;


CePP: cerebral perfusion pressure;


CoPP: Coronary perfusion pressure;


ETCO2: end tidal CO2 (mmHg);


AMSA: amplitude spectral area (mV-Hz);


CBF: Mean carotid blood flow (ml/min). Those are r.







FIG. 5 demonstrates the correlation between AMSA and ETCO2: STD CPR (diamond); STD CPR+ITD (square); and ACD CPR+ITD (triangle).


The Bland-Altman analysis indicated the 95% limits of agreement between AMSA and ETCO ranged from −21.4 to −33.5. This is shown graphically in FIG. 6: STD CPR (diamond); STD CPR+ITD (square); and ACD CPR+ITD (triangle). These study results indicate a strong association between AMSA and ETCO2.


Research has conventionally focused on finding a non-invasive method to predict the success of defibrillation with the hope of having a substantial impact on the survival outcome of patients. AMSA has been reported to provide an 86% positive and an 85% negative predictive value, respectively for a threshold value at 21 mV x Hz. However AMSA values can be difficult to calculate in real-time and are not recommended for routine use in the guideline for defibrillation management in adult cardiac arrest in the clinical setting in or out-of-hospital. By contrast, continuous ETCO2 waveforms are readily obtainable and can be rapidly analyzed. Using three different methods of CPR to consistently vary different organ perfusion levels, a correlation between ETCO2 and AMSA is demonstrated. Because of this newly discovered correlation, techniques for using ETCO2 values, alone or in combination with AMSA values, to direct a caregivers are proposed as to when to apply a defibrillating shock. More specifically, if the measured ETCO2 values are within an acceptable range or near an acceptable value, an indication may be supplied to the caregiver as to when to apply a defibrillating shock.



FIG. 7 shows an example treatment system 700 in accordance with the present disclosure. The system 700 may include a facial mask 702 and a valve system 704. The valve system 704 may be coupled to a controller 706. In turn, the controller 706 may be used to control an impedance level of the valve system 704. The level of impedance may be varied based on measurements of physiological parameters, or using a programmed schedule of changes. The system 700 may include a wide variety of sensors and/or measuring devices to measure any of a number physiological parameters. Such sensors or measuring devices may be integrated within or coupled to the valve system 704, the facial mask 702, etc., or may be separate depending on implementation. An example of sensors and/or measuring devices may include a pressure transducer for taking pressure measurements (such as intrathoracic pressures, intracranial pressures, intraocular pressures), a flow rate measuring device for measuring the flow rate of air into or out of the lungs, or a CO2 sensor for measuring expired CO2. Examples of other sensors or measuring devices include a heart rate sensor 708, a blood pressure sensor 710, and a temperature sensor 712. These sensors may also be coupled to the controller 706 so that measurements may be recorded. Further, it will be appreciated that other types of sensors and/or devices may be coupled to the controller 706 and may be used to implement defibrillation and measure various physiological parameters, such as bispectral index, oxygen saturation and/or blood levels of O2, blood lactate, blood pH, tissue lactate, tissue pH, blood pressure, pressures within the heart, intrathoracic pressures, positive end expiratory pressure, respiratory rate, intracranial pressures, intraocular pressures, respiratory flow, oxygen delivery, temperature, end-tidal CO2, tissue CO2, cardiac output, and many others.


For example, ECG electrode(s) or sensor(s) 720 may also be coupled to the controller 706 so that measurements related to the electrical activity of an individual's heart may be monitored and recorded. Advantageously, this may allow for the acquisition and/or derivation of AMSA values of a particular individual during a CPR procedure, as discussed throughout the present disclosure. Additionally, a display screen 722 and one or more speakers 724 may be coupled to the controller 706 to provide a prompt to a rescuer, such as a prompt to “cue” a rescuer to defibrillate an individual while CPR is performed on the individual. Such a feature is discussed in further detail in connection with at least FIG. 8. Even further, one or more electrodes 726 may be coupled to the controller 706 to enable application of a defibrillation shock(s) either automatically (e.g., without direct user-input) or manually (e.g., in response to activation of a particular “button”). Still many other devices, sensors, etc., may be coupled to the controller 706 as needed or desired, to implement the various features or aspects of the present disclosure.


In some cases, the controller 706 may be used to control the valve system 704, to control any sensors or measuring devices, to record measurements, and to perform any comparisons. Alternatively, a set of computers and/or controllers may be used in combination to perform such tasks. This equipment may have appropriate processors, display screens, input and output devices, entry devices, memory or databases, software, and the like needed to operate the system 700. A variety of devices may also be coupled to controller to cause the person to artificially inspire. For example, such devices may comprise a ventilator 714, an iron lung cuirass device 716 or a phrenic nerve stimulator 718. The ventilator 714 may be configured to create a negative intrathoracic pressure within the person, or may be a high frequency ventilator capable of generating oscillations at about 200 to about 2000 per minute. Other embodiments are possible.



FIG. 8 shows an example computer system or device 800 in accordance with the present disclosure. An example of a computer system or device includes a medical device, a desktop computer, a laptop computer, a tablet computer, and/or any other type of machine configured for performing calculations. The example computer device 800 may be configured to perform and/or include instructions that, when executed, cause the computer system 800 to perform a method for providing a guide to determine when to defibrillate an individual using ETCO2 measurements alone. The example computer device 800 may be configured to perform and/or include instructions that, when executed, cause the computer system 800 to perform a method for providing a guide to determine when to defibrillate an individual using ETCO2 measurements and AMSA values. The particular trigger of when to provide the shock may be based on part on the correlation between the ETCO2 measurements and predetermined AMSA values, or may be determined empirically based on test data using ETCO2 measurements. It is thus contemplated that the example computer device 800 may be coupled to one or more sensors configured and arranged to acquire and/or operate on such measurements or data, itself have integrated therein one or more sensors configured and arranged to acquire and/or operate on such measurements or data, or any combination thereof.


Furthermore, it is contemplated that the example computer system 800 may include or comprise at least one of an audio speaker and a display monitor so as to provide at least one of an audio indication (e.g., a particular tone or series of tones such as a single or periodic or intermittent “beep,” a particular word such as a “go” or “defibrillate,” and etc.) and a visual indication (e.g., a particular colored screen or series of screens such as a “green” screen or periodically or intermittently “flashing” screens of one or more particular colors, a particular graphic such as a “go” or “defibrillate,” and etc.) so that a medical professional or other individual may be “cued” to defibrillate an individual during CPR as performed on the individual as discussed throughout the present disclosure. Such features may be embodied by the output device(s) 808 shown in FIG. 8 discussed further below.


The computer device 800 is shown comprising hardware elements that may be electrically coupled via a bus 802 (or may otherwise be in communication, as appropriate). The hardware elements may include a processing unit with one or more processors 804, including without limitation one or more general-purpose processors and/or one or more special-purpose processors (such as digital signal processing chips, graphics acceleration processors, and/or the like); one or more input devices 806, which may include without limitation a remote control, a mouse, a keyboard, and/or the like; and one or more output devices 808, which may include without limitation, a video monitor or screen, an audio speaker, a printer, and/or the like.


The computer system 800 may further include (and/or be in communication with) one or more non-transitory storage devices 810, which may comprise, without limitation, local and/or network accessible storage, and/or may include, without limitation, a disk drive, a drive array, an optical storage device, a solid-state storage device, such as a random access memory, and/or a read-only memory, which may be programmable, flash-updateable, and/or the like. Such storage devices may be configured to implement any appropriate data stores, including without limitation, various file systems, database structures, and/or the like.


The computer device 800 might also include a communications subsystem 812, which may include without limitation a modem, a network card (wireless or wired), an infrared communication device, a wireless communication device, and/or a chipset, such as a Bluetooth™ device, an 802.11 device, a WiFi device, a WiMax device, hardwired and/or wireless communication facilities, and/or the like. The communications subsystem 812 may permit data to be exchanged with a private and/or non-private network, other computer systems, and/or any other devices described herein. In many embodiments, the computer system 800 may further comprise a working memory 814, which may include a random access memory and/or a read-only memory device, as described above.


The computer device 800 also may comprise software elements, shown as being currently located within the working memory 814, including an operating system 816, device drivers, executable libraries, and/or other code, such as one or more application programs 818, which may comprise computer programs provided by various embodiments, and/or may be designed to implement methods, and/or configure systems, provided by other embodiments, as described herein. By way of example, one or more procedures described with respect to the method(s) discussed above, and/or system components might be implemented as code and/or instructions executable by a computer (and/or a processor within a computer); in an aspect, then, such code and/or instructions may be used to configure and/or adapt a general purpose computer (or other device) to perform one or more operations in accordance with the described methods.


A set of these instructions and/or code might be stored on a non-transitory computer-readable storage medium, such as the storage device(s) 810 described above. In some cases, the storage medium might be incorporated within a computer system, such as computer system 800. In other embodiments, the storage medium might be separate from a computer system (e.g., a removable medium, such as flash memory), and/or provided in an installation package, such that the storage medium may be used to program, configure, and/or adapt a general purpose computer with the instructions/code stored thereon. These instructions might take the form of executable code, which is executable by the computer device 800 and/or might take the form of source and/or installable code, which, upon compilation and/or installation on the computer system 800 (e.g., using any of a variety of generally available compilers, installation programs, compression/decompression utilities, etc.), then takes the form of executable code.


It will be apparent to those skilled in the art that substantial variations may be made in accordance with specific requirements. For example, customized hardware might also be used, and/or particular elements might be implemented in hardware, software (including portable software, such as applets, etc.), or both. Further, connection to other computing devices such as network input/output devices may be employed.


As mentioned above, in one aspect, some embodiments may employ a computer system (such as the computer device 800) to perform methods in accordance with various embodiments of the invention. According to a set of embodiments, some or all of the procedures of such methods are performed by the computer system 800 in response to processor 804 executing one or more sequences of one or more instructions (which might be incorporated into the operating system 816 and/or other code, such as an application program 818) contained in the working memory 814. Such instructions may be read into the working memory 814 from another computer-readable medium, such as one or more of the storage device(s) 810. Merely by way of example, execution of the sequences of instructions contained in the working memory 814 may cause the processor(s) 804 to perform one or more procedures of the methods described herein.


The terms “machine-readable medium” and “computer-readable medium,” as used herein, may refer to any medium that participates in providing data that causes a machine to operate in a specific fashion. In an embodiment implemented using the computer device 800, various computer-readable media might be involved in providing instructions/code to processor(s) 804 for execution and/or might be used to store and/or carry such instructions/code. In many implementations, a computer-readable medium is a physical and/or tangible storage medium. Such a medium may take the form of a non-volatile media or volatile media. Non-volatile media may include, for example, optical and/or magnetic disks, such as the storage device(s) 810. Volatile media may include, without limitation, dynamic memory, such as the working memory 814.


Example forms of physical and/or tangible computer-readable media may include a floppy disk, a flexible disk, hard disk, magnetic tape, or any other magnetic medium, a CD-ROM, any other optical medium, a RAM, a PROM, EPROM, a FLASH-EPROM, any other memory chip or cartridge, or any other medium from which a computer may read instructions and/or code.


Various forms of computer-readable media may be involved in carrying one or more sequences of one or more instructions to the processor(s) 804 for execution. By way of example, the instructions may initially be carried on a magnetic disk and/or optical disc of a remote computer. A remote computer might load the instructions into its dynamic memory and send the instructions as signals over a transmission medium to be received and/or executed by the computer system 800.


The communications subsystem 812 (and/or components thereof) generally will receive signals, and the bus 802 then might carry the signals (and/or the data, instructions, etc. carried by the signals) to the working memory 814, from which the processor(s) 804 retrieves and executes the instructions. The instructions received by the working memory 814 may optionally be stored on a non-transitory storage device 810 either before or after execution by the processor(s) 804.


As may be understood from the foregoing discussion in connection with the drawings, it is contemplated that ETCO2 measurements may be used alone as a guide to determine when to defibrillate an individual. Alternatively, ETCO2 measurements may be used in combination with amplitude spectral area measurements as a guide to determine when to defibrillate an individual.


In particular, in some aspects, a computer-implemented method may include or comprise obtaining, by a computing or measuring system, an ETCO2 measurement of an individual during a CPR procedure performed on the individual. The method may further include or comprise comparing, by the computing system, a particular ETCO2 value derived from the ETCO2 measurement to a predetermined threshold value. The method may further include or comprise providing, by the computing system based on the comparing, a perceivable indication that designates a time to deliver a defibrillation shock to the individual. Further, the computing system may, in some embodiments, use a change from one time point to the next or another, in ETCO2 measurements, to determine the time to delivery of a defibrillation shock. The ETCO2 measurements could include peak and/or trough ETCO2 values, mean values, or ETCO2 waveform characteristics which are affected by the amount of blood circulating or in circulation during CPR in the individual.


Additionally, or alternatively, the method may include or comprise providing the indication when the particular ETCO2 value is less than or equal to the predetermined threshold value. For example, when ETCO2 levels are persistently less than 10 mmHg, then the chances for a successful defibrillation may be considered to be extremely low and such information may be used by the computing system to determine that a defibrillatory shock should not be delivered at that time. Additionally, or alternatively, the method may include or comprise providing the indication when the particular ETCO2 value is greater than or equal to the predetermined threshold value.


Additionally, or alternatively, the method may include or comprise providing, by the computing system based on the comparison, at least one of an audio indication and a visual indication that designates the time to deliver the defibrillation shock to the individual. The visual indication could be provided in the form of an absolute number or a graph of changes in ETCO2 or a derivative of ETCO2 over time, with an indication for the threshold value needed before a shock should be delivered.


Additionally, or alternatively, the method may include or comprise obtaining an electrocardiogram (ECG) measurement of the individual during the CPR procedure; deriving from the ECG measurement an amplitude spectral area value; and providing the indication that designates the time to deliver the defibrillation shock to the individual based upon the amplitude spectrum area value and the comparison of the ETCO2 value to the predetermined threshold value. For example, both AMSA and ETCO2 values would have to be at a threshold value before a shock is delivered, thereby providing the greatest likelihood for a successful defibrillation and survival. In this manner, the computing system may take into account both measurements before advising or triggering a defibrillatory shock. Other potential combinations of these two distinctly different physiological signals to provide a greater degree of predictive certainty of defibrillation success or failure include the value obtained by multiplying, or performing another mathematical operation, the ETCO2 and AMSA values together to achieve a number that would provide an indicator that defibrillation would be successful.


In some aspects, a method may include or comprise performing a cardiopulmonary resuscitation (CPR) procedure on an individual; and delivering a defibrillation shock to the individual at a particular time based upon an indication provided by a computing system when a particular end-tidal carbon dioxide (ETCO2) value derived from an ETCO2 measurement of the individual during the CPR procedure is determined by the computing system as less than or greater than a predetermined threshold value. In some embodiments, once the rescuer observes the indication, then they would deliver the defibrillatory shock within the next 30-60 seconds. In cases where the shock is not successful, a follow-up ETCO2 value could be used to determine if an additional 1-2 minutes of CPR is needed or whether the rescuer should charge the defibrillator and immediately deliver another shock. Thus, the post shock ETCO2 value could be used to help determine the timing of follow up shocks if the first one is not successful. The computing system may adjust for the failed shock such that the next shock would not be advised unless the ETCO2 values were higher, for example, 10% higher than those measured prior to the first shock.


Additionally, or alternatively, the method may include or comprise performing an intrathoracic pressure regulation procedure or a reperfusion injury protection procedure at or during the CPR procedure. Additionally, or alternatively, the method may include or comprise periodically extracting respiratory gases from the airway of the individual to create an intrathoracic vacuum that lowers pressure in the thorax to at least one of: enhance the flow of blood to the heart of the individual; lower intracranial pressures of the individual; and enhance cerebral profusion pressures of the individual. Additionally, or alternatively, the method may include or comprise preventing air from at least temporarily entering the lungs of the individual during at least a portion of a relaxation or decompression phase of the CPR procedure to create an intrathoracic vacuum that lowers pressure in the thorax to at least one of: enhance flow of blood to the heart of the particular individual; lower intracranial pressures of the particular individual; and enhance cerebral profusion pressures of the individual. The methods and devices used to perform CPR could include manual closed chest CPR, CPR with an active compression decompression device, and such CPR methods could be used together with an impedance threshold device to transiently impede inspiratory flow during the recoil phase of CPR or an intrathoracic pressure regulatory to actively extract gases form the lungs.


Additionally, or alternatively, the method may include or comprise performing a standard CPR procedure on the individual. Additionally, or alternatively, the method may include or comprise performing a stutter CPR procedure on the individual to achieve some degree of reperfusion injury protection. Additionally, or alternatively, the method may include or comprise performing an active compression-decompression CPR procedure on the individual. Additionally, or alternatively, the method may include or comprise positioning a mechanical CPR device relative to the chest of the individual; and activating the mechanical CPR device to perform a mechanized CPR procedure on the individual. Such CPR devices could include, but would not be limited to, a LUCAS device (Physio-control, Redmond, Wash.). The Zoll Autopulse (Chelmsford, Mass.), the Michigan Instrument Thumper (Grand Rapids, Mich.).


Additionally, or alternatively, the method may include or comprise delivering the defibrillation shock to the individual upon perception of the indication provided by the computing system at the particular time based upon an amplitude spectrum area value of the individual as derived from a measurement during the CPR procedure and when the particular ETCO2 value is determined as less than or equal, or greater than or equal to the predetermined threshold value. Additionally, or alternatively, the method may include or comprise delivering the defibrillation shock to the individual upon perception of at least one of an audio indication and a visual indication provided by the computing system.


In some aspects, a system, device, or apparatus may include or comprise a first device that monitors concentration of carbon dioxide in respiratory gases of an individual at least during a cardiopulmonary resuscitation (CPR) procedure performed on the individual; a second device that compares a particular end-tidal carbon dioxide value derived from the concentration of carbon dioxide in respiratory gases of the individual to a predetermined threshold value; and a third device that provides based on the comparison a perceivable indication that designates a time to deliver a defibrillation shock to the individual. The second device may be used with the third device to determine the optimal time to deliver the shock and, if the first shock fails, may use the same or different logic to determine the time to deliver additional shocks.


Additionally, or alternatively, the system, device, or apparatus may include or comprise an electroencephalogram (EEG) sensor that measures an EEG signal of the individual at least during the CPR procedure performed on the individual, wherein the second device derives an amplitude spectrum area value from the EEG signal, and the third device provides the perceivable indication based upon the amplitude spectrum area value and the comparison of the particular end-tidal carbon dioxide value to the predetermined threshold value. Additionally, or alternatively, the system, device, or apparatus may include or comprise a circulation enhancement device that enhances circulation of the individual at least during the CPR procedure performed on the individual.


The methods, systems, and devices discussed above are examples. Various configurations may omit, substitute, or add various method steps or procedures, or system components as appropriate. For instance, in alternative configurations, the methods may be performed in an order different from that described, and/or various stages may be added, omitted, and/or combined. Also, features described with respect to certain configurations may be combined in various other configurations. Different aspects and elements of the configurations may be combined in a similar manner. Also, technology evolves and, thus, many of the elements are examples and do not limit the scope of the disclosure or claims.


Specific details are given in the description to provide a thorough understanding of example configurations (including implementations). However, configurations may be practiced without these specific details. For example, well-known circuits, processes, algorithms, structures, and techniques have been shown without unnecessary detail in order to avoid obscuring the configurations. This description provides example configurations only, and does not limit the scope, applicability, or configurations of the claims. Rather, the preceding description of the configurations will provide those skilled in the art with an enabling description for implementing described techniques. Various changes may be made in the function and arrangement of elements without departing from the spirit or scope of the disclosure.


Also, configurations may be described as a process which is depicted as a flow diagram or block diagram. Although each may describe the operations as a sequential process, many of the operations may be performed in parallel or concurrently. In addition, the order of the operations may be rearranged. A process may have additional steps not included in the figure. Furthermore, examples of the methods may be implemented by hardware, software, firmware, middleware, microcode, hardware description languages, or any combination thereof. When implemented in software, firmware, middleware, or microcode, the program code or code segments to perform the necessary tasks may be stored in a non-transitory computer-readable medium such as a storage medium. Processors may perform the described tasks.


Furthermore, the example embodiments described herein may be implemented as logical operations in a computing device in a networked computing system environment. The logical operations may be implemented as: (i) a sequence of computer implemented instructions, steps, or program modules running on a computing device; and (ii) interconnected logic or hardware modules running within a computing device.


Although the subject matter has been described in language specific to structural features and/or methodological acts, it is to be understood that the subject matter defined in the appended claims is not necessarily limited to the specific features or acts described above. Rather, the specific features and acts described above are disclosed as example forms of implementing the claims.

Claims
  • 1. A defibrillation device for guiding defibrillation therapy of an individual during resuscitation, comprising: an end-tidal carbon dioxide (ETCO2) sensor for obtaining signals representing ETCO2 of the individual;an electrocardiogram (ECG) sensor for obtaining signals representing ECG of the individual; anda processor in communication with the ETCO2 sensor and the ECG sensor and configured to: receive and process the signals representing ETCO2 from the ETCO2 sensor to generate ETCO2 data,receive and process the signals representing ECG from the ECG sensor to generate ECG data,analyze the ETCO2 data and the ECG data, the analysis of the ECG data being frequency-based,determine, based on the analysis of the ETCO2 data and the ECG data, whether a defibrillation shock should be delivered to the individual, andprovide an indication that designates whether the defibrillation shock should be delivered.
  • 2. The device of claim 1, wherein the determination is based on whether the ETCO2 data is higher or lower than a first predetermined threshold value.
  • 3. The device of claim 2, wherein the predetermined threshold value is from 5 mmHg to 20 mmHg.
  • 4. The device of claim 1, wherein the processor is configured to perform a frequency domain transform on the ECG data.
  • 5. The device of claim 4, wherein the frequency domain transform results in an amplitude spectrum area (AMSA) value.
  • 6. The device of claim 5, wherein the determination is further based on whether the AMSA value is higher or lower than a second predetermined threshold value.
  • 7. The device of claim 6, wherein the second predetermined threshold value is from 31 mV-Hz to 45 mV-Hz.
  • 8. The device of claim 1, wherein the determination is based on analysis of both the ECG data and the ETCO2 data.
  • 9. The device of claim 8, wherein the determination is based on a comparison of the ECG data to a first predetermined threshold and a comparison of the ETCO2 data to a second predetermined threshold value.
  • 10. The device of claim 1, further comprising a display, and wherein the processor is configured to provide the indication of whether the defibrillation shock should be delivered on the display.
  • 11. The device of claim 10, wherein the indication comprises a prompt on the display instructing a user as to the proper time to deliver the defibrillating shock.
  • 12. The device of claim 1, further comprising one or more speakers for providing the indication of whether the defibrillation shock should be delivered.
  • 13. The device of claim 12, wherein the indication comprises a prompt instructing a user as to a proper time to deliver the defibrillating shock.
  • 14. The device of claim 1, further comprising a defibrillator.
  • 15. The device of claim 14, further comprising further comprising defibrillation electrodes.
  • 16. The device of claim 14, wherein the processor is configured to instruct the defibrillator to provide the defibrillating shock based on the determination.
  • 17. The device of claim 1, further comprising one or more additional sensors.
  • 18. The device of claim 17, wherein the one or more additional sensors are one or more of a heart rate sensor, a blood pressure sensor, a temperature sensor, a bispectral index sensor, an oxygen sensor, a blood lactate sensor, a blood pH sensor, a tissue lactate sensor, a tissue pH sensor, an intracardiac pressure sensor, an intrathoracic pressure sensor, a positive end expiratory pressure sensor, a respiratory rate sensor, an intracranial pressure sensor, an intraocular pressure sensor, a respiratory flow sensor, an oxygen delivery sensor, a tissue CO2 sensor, and a cardiac output sensor.
  • 19. The device of claim 1, wherein the processor is in communication with one or more circulation enhancement devices.
  • 20. The device of claim 19, wherein the circulation enhancement device is configured to generate a negative intrathoracic pressure within a patient.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of co-pending U.S. patent application Ser. No. 15/420,653, filed Jan. 31, 2017, which is a continuation of U.S. patent application Ser. No. 14/292,578, filed May 30, 2014, now abandoned, which claims priority to U.S. Provisional Patent Application No. 61/829,176 filed May 30, 2013, entitled END TIDAL CARBON DIOXIDE AND AMPLITUDE SPECTRAL AREA AS NON-INVASIVE MARKERS OF CORONARY PERFUSION PRESSURE AND ARTERIAL PRESSURE, the entire disclosures of which are hereby incorporated by reference, for all purposes, as if fully set forth herein.

US Referenced Citations (389)
Number Name Date Kind
1848232 Swope et al. Mar 1932 A
2325049 Frye et al. Jul 1943 A
2774346 Halliburton Dec 1956 A
2854982 Pagano Oct 1958 A
2904898 Marsden Sep 1959 A
3009266 Brook Nov 1961 A
3049811 Ruben Aug 1962 A
3068590 Padellford Dec 1962 A
3077884 Batrow et al. Feb 1963 A
3191596 Bird et al. Jun 1965 A
3199225 Robertson et al. Aug 1965 A
3209469 James Oct 1965 A
3216413 Arecheta Mota Nov 1965 A
3274705 Breakspear Sep 1966 A
3276147 Padellford Oct 1966 A
3307541 Hewson Mar 1967 A
3357426 Cohen Dec 1967 A
3420232 Bickford Jan 1969 A
3459216 Bloom et al. Aug 1969 A
3467092 Bird et al. Sep 1969 A
3509899 Hewson May 1970 A
3515163 Freeman Jun 1970 A
3523529 Kissen Aug 1970 A
3552390 Muller Jan 1971 A
3562924 Baerman et al. Feb 1971 A
3562925 Baermann et al. Feb 1971 A
3568333 Clark Mar 1971 A
3662751 Barkalow et al. May 1972 A
3669108 Sundblom et al. Jun 1972 A
3734100 Walker et al. May 1973 A
3739776 Bird et al. Jun 1973 A
3794043 McGinnis Feb 1974 A
3815606 Mazal Jun 1974 A
3834383 Weigl et al. Sep 1974 A
3872609 Smrcka Mar 1975 A
3874093 Garbe Apr 1975 A
3875626 Tysk et al. Apr 1975 A
3933171 Hay Jan 1976 A
3949388 Fuller Apr 1976 A
3973564 Carden Aug 1976 A
3981398 Boshoff Sep 1976 A
3993059 Sjostrand Nov 1976 A
4037595 Elam Jul 1977 A
4041943 Miller Aug 1977 A
4054134 Kritzer Oct 1977 A
4077400 Harrigan Mar 1978 A
4077404 Elam Mar 1978 A
4095590 Harrigan Jun 1978 A
4166458 Harrigan Sep 1979 A
4193406 Jinotti Mar 1980 A
4198963 Barkalow et al. Apr 1980 A
4226233 Kritzer Oct 1980 A
4237872 Harrigan Dec 1980 A
4240419 Furlong et al. Dec 1980 A
4259951 Chernack et al. Apr 1981 A
4262667 Grant Apr 1981 A
4297999 Kitrell Nov 1981 A
4298023 McGinnis Nov 1981 A
4316458 Hammerton-Fraser Feb 1982 A
4320754 Watson et al. Mar 1982 A
4326507 Barkalow Apr 1982 A
4331426 Sweeney May 1982 A
4349015 Alferness Sep 1982 A
4360345 Hon Nov 1982 A
4397306 Weisfeldt et al. Aug 1983 A
4424806 Newman et al. Jan 1984 A
4446864 Watson et al. May 1984 A
4448192 Stawitcke et al. May 1984 A
4449526 Elam May 1984 A
4481938 Lindley Nov 1984 A
4501582 Schulz Feb 1985 A
4513737 Mabuchi Apr 1985 A
4519388 Schwanbom et al. May 1985 A
4520811 White et al. Jun 1985 A
4533137 Sonne Aug 1985 A
4543951 Phuc Oct 1985 A
4588383 Parker et al. May 1986 A
4598706 Darowski et al. Jul 1986 A
4601465 Roy Jul 1986 A
4602653 Ruiz-Vela et al. Jul 1986 A
4637386 Baum Jan 1987 A
4738249 Linman et al. Apr 1988 A
4750493 Brader Jun 1988 A
4774941 Cook Oct 1988 A
4797104 Laerdal et al. Jan 1989 A
4807638 Sramek Feb 1989 A
4809683 Hanson Mar 1989 A
4827935 Geddes et al. May 1989 A
4828501 Ingenito et al. May 1989 A
4863385 Pierce Sep 1989 A
4881527 Lerman Nov 1989 A
4898166 Rose et al. Feb 1990 A
4898167 Pierce et al. Feb 1990 A
4928674 Halperin et al. May 1990 A
4932879 Ingenito et al. Jun 1990 A
4971042 Lerman Nov 1990 A
4971051 Toffolon Nov 1990 A
4984987 Brault et al. Jan 1991 A
5014698 Cohen May 1991 A
5016627 Dahrendorf et al. May 1991 A
5029580 Radford et al. Jul 1991 A
5042500 Norlien et al. Aug 1991 A
5050593 Poon Sep 1991 A
5056505 Warwick et al. Oct 1991 A
5083559 Brault et al. Jan 1992 A
5109840 Daleiden May 1992 A
5119825 Huhn Jun 1992 A
5150291 Cummings et al. Sep 1992 A
5163424 Kohnke Nov 1992 A
5183038 Hoffman et al. Feb 1993 A
5184620 Cudahy et al. Feb 1993 A
5188098 Hoffman et al. Feb 1993 A
5193529 Labaere Mar 1993 A
5193544 Jaffe Mar 1993 A
5195896 Sweeney et al. Mar 1993 A
5217006 McCulloch Jun 1993 A
5231086 Sollevi Jul 1993 A
5235970 Augustine Aug 1993 A
5238409 Brault et al. Aug 1993 A
5239988 Swanson et al. Aug 1993 A
5263476 Henson Nov 1993 A
5265595 Rudolph Nov 1993 A
5282463 Hammersley Feb 1994 A
5295481 Geeham Mar 1994 A
5301667 McGrail et al. Apr 1994 A
5305743 Brain Apr 1994 A
5306293 Zacouto Apr 1994 A
5312259 Flynn May 1994 A
5313938 Garfield et al. May 1994 A
5316907 Lurie et al. May 1994 A
5330514 Egelandsdal et al. Jul 1994 A
5335654 Rapoport Aug 1994 A
5353788 Miles Oct 1994 A
5355879 Brain Oct 1994 A
5359998 Lloyd Nov 1994 A
5366231 Hung Nov 1994 A
5377671 Biondi et al. Jan 1995 A
5383786 Kohnke Jan 1995 A
5385547 Wong et al. Jan 1995 A
5388575 Taube Feb 1995 A
5392774 Sato Feb 1995 A
5395399 Rosenwald Mar 1995 A
5397237 Dhont et al. Mar 1995 A
5398714 Price Mar 1995 A
5413110 Cummings et al. May 1995 A
5423685 Adamson et al. Jun 1995 A
5423772 Lurie et al. Jun 1995 A
5425742 Joy Jun 1995 A
5437272 Fuhrman Aug 1995 A
5452715 Boussignac Sep 1995 A
5454779 Lurie et al. Oct 1995 A
5458562 Cooper Oct 1995 A
5468151 Egelandsdal et al. Nov 1995 A
5474533 Ward et al. Dec 1995 A
5477860 Essen-Moller Dec 1995 A
5490820 Schock et al. Feb 1996 A
5492115 Abramov et al. Feb 1996 A
5492116 Scarberry et al. Feb 1996 A
5496257 Kelly Mar 1996 A
5517986 Starr et al. May 1996 A
5544648 Fischer, Jr. Aug 1996 A
5549106 Gruenke et al. Aug 1996 A
5549581 Lurie et al. Aug 1996 A
5551420 Lurie et al. Sep 1996 A
5557049 Ratner Sep 1996 A
5580255 Flynn Dec 1996 A
5582182 Hillsman Dec 1996 A
5588422 Lurie et al. Dec 1996 A
5593306 Kohnke Jan 1997 A
5614490 Przybelski Mar 1997 A
5617844 King Apr 1997 A
5618665 Lurie et al. Apr 1997 A
5619665 Emma Apr 1997 A
5628305 Melker May 1997 A
5632298 Artinian May 1997 A
5643231 Lurie et al. Jul 1997 A
5645522 Lurie et al. Jul 1997 A
5657751 Karr, Jr. Aug 1997 A
5678535 DiMarco Oct 1997 A
5685298 Idris Nov 1997 A
5692498 Lurie et al. Dec 1997 A
5697364 Chua et al. Dec 1997 A
5701883 Hete et al. Dec 1997 A
5701889 Danon Dec 1997 A
5704346 Inoue Jan 1998 A
5720282 Wright Feb 1998 A
5722963 Lurie et al. Mar 1998 A
5730122 Lurie Mar 1998 A
5735876 Kroll et al. Apr 1998 A
5738637 Kelly et al. Apr 1998 A
5743864 Baldwin, II Apr 1998 A
5782883 Kroll et al. Jul 1998 A
5794615 Estes Aug 1998 A
5806512 Abramov et al. Sep 1998 A
5814086 Hirschberg et al. Sep 1998 A
5817997 Wernig Oct 1998 A
5823185 Chang Oct 1998 A
5823787 Gonzalez et al. Oct 1998 A
5827893 Lurie et al. Oct 1998 A
5832920 Field Nov 1998 A
5853292 Eggert et al. Dec 1998 A
5881725 Hoffman et al. Mar 1999 A
5885084 Pastrick et al. Mar 1999 A
5891062 Schock et al. Apr 1999 A
5896857 Hely et al. Apr 1999 A
5916165 Duchon et al. Jun 1999 A
5919210 Lurie et al. Jul 1999 A
5927273 Federowicz et al. Jul 1999 A
5937853 Strom Aug 1999 A
5941710 Lampotang et al. Aug 1999 A
5975081 Hood et al. Nov 1999 A
5977091 Nieman et al. Nov 1999 A
5984909 Lurie et al. Nov 1999 A
5988166 Hayek Nov 1999 A
6001085 Lurie et al. Dec 1999 A
6010470 Albery et al. Jan 2000 A
6029667 Lurie Feb 2000 A
6042532 Freed et al. Mar 2000 A
6062219 Lurie et al. May 2000 A
6078834 Lurie et al. Jun 2000 A
6086582 Altman et al. Jul 2000 A
6123074 Hete et al. Sep 2000 A
6131571 Lampotang et al. Oct 2000 A
6155257 Lurie et al. Dec 2000 A
6155647 Albecker, III Dec 2000 A
6165105 Boutellier et al. Dec 2000 A
6167879 Sievers et al. Jan 2001 B1
6174295 Cantrell et al. Jan 2001 B1
6176237 Wunderlich et al. Jan 2001 B1
6193519 Eggert et al. Feb 2001 B1
6209540 Sugiura et al. Apr 2001 B1
6224562 Lurie et al. May 2001 B1
6234916 Carusillo et al. May 2001 B1
6234985 Lurie et al. May 2001 B1
6277107 Lurie et al. Aug 2001 B1
6296490 Bowden Oct 2001 B1
6312399 Lurie et al. Nov 2001 B1
6334441 Zowtiak et al. Jan 2002 B1
6356785 Snyder et al. Mar 2002 B1
6369114 Weil et al. Apr 2002 B1
6374827 Bowden et al. Apr 2002 B1
6390996 Halperin et al. May 2002 B1
6425393 Lurie et al. Jul 2002 B1
6439228 Hete et al. Aug 2002 B1
6459933 Lurie et al. Oct 2002 B1
6463327 Lurie et al. Oct 2002 B1
6486206 Lurie Nov 2002 B1
6526970 DeVries et al. Mar 2003 B2
6526973 Lurie et al. Mar 2003 B1
6536432 Truschel Mar 2003 B2
6544172 Toeppen-Sprigg Apr 2003 B2
6555057 Barbut et al. Apr 2003 B1
6578574 Kohnke Jun 2003 B1
6584973 Biondi et al. Jul 2003 B1
6587726 Lurie et al. Jul 2003 B2
6595213 Bennarsten Jul 2003 B2
6604523 Lurie et al. Aug 2003 B2
6622274 Lee et al. Sep 2003 B1
6622724 Truitt et al. Sep 2003 B1
6631716 Robinson et al. Oct 2003 B1
6656166 Lurie et al. Dec 2003 B2
6662032 Gavish et al. Dec 2003 B1
6676613 Cantrell et al. Jan 2004 B2
6726634 Freeman Apr 2004 B2
6729334 Baran May 2004 B1
6758217 Younes Jul 2004 B1
6776156 Lurie et al. Aug 2004 B2
6780017 Pastrick et al. Aug 2004 B2
6792947 Bowden Sep 2004 B1
6860265 Emerson Mar 2005 B1
6863656 Lurie Mar 2005 B2
6877511 DeVries et al. Apr 2005 B2
6935336 Lurie et al. Aug 2005 B2
6938618 Lurie et al. Sep 2005 B2
6986349 Lurie Jan 2006 B2
6988499 Holt et al. Jan 2006 B2
7011622 Kuyava et al. Mar 2006 B2
7032596 Thompson et al. Apr 2006 B2
7044128 Lurie et al. May 2006 B2
7066173 Banner et al. Jun 2006 B2
7082945 Lurie Aug 2006 B2
7096866 Be'eri et al. Aug 2006 B2
7174891 Lurie et al. Feb 2007 B2
7185649 Lurie Mar 2007 B2
7188622 Martin et al. Mar 2007 B2
7195012 Lurie Mar 2007 B2
7195013 Lurie Mar 2007 B2
7204251 Lurie Apr 2007 B2
7210480 Lurie et al. May 2007 B2
7220235 Geheb et al. May 2007 B2
7226427 Steen Jun 2007 B2
7275542 Lurie et al. Oct 2007 B2
7311668 Lurie Dec 2007 B2
7469700 Baran Dec 2008 B2
7487773 Li Feb 2009 B2
7500481 Delache et al. Mar 2009 B2
7571725 Wickham et al. Aug 2009 B2
7594508 Doyle Sep 2009 B2
7650181 Freeman et al. Jan 2010 B2
7682312 Lurie Mar 2010 B2
7766011 Lurie Aug 2010 B2
7793659 Breen Sep 2010 B2
7836881 Lurie et al. Nov 2010 B2
7899526 Benditt et al. Mar 2011 B2
8011367 Lurie et al. Sep 2011 B2
8108204 Gabrilovich et al. Jan 2012 B2
8151790 Lurie et al. Apr 2012 B2
8210176 Metzger et al. Jul 2012 B2
8287474 Koenig et al. Oct 2012 B1
8388682 Hendricksen et al. Mar 2013 B2
8408204 Lurie Apr 2013 B2
8702633 Voss et al. Apr 2014 B2
8755902 Lurie et al. Jun 2014 B2
8882703 Hickle Nov 2014 B2
8939922 Strand et al. Jan 2015 B2
20010003984 Bennarsten et al. Jun 2001 A1
20010029339 Orr et al. Oct 2001 A1
20010047140 Freeman Nov 2001 A1
20020007832 Doherty Jan 2002 A1
20020069878 Lurie et al. Jun 2002 A1
20020104544 Ogushi et al. Aug 2002 A1
20020170562 Lurie et al. Nov 2002 A1
20020179090 Boussignac Dec 2002 A1
20030000526 Gobel Jan 2003 A1
20030037784 Lurie Feb 2003 A1
20030062040 Lurie et al. Apr 2003 A1
20030062041 Keith et al. Apr 2003 A1
20030192547 Lurie et al. Oct 2003 A1
20040016428 Lurie Jan 2004 A9
20040058305 Lurie et al. Mar 2004 A1
20040200473 Lurie et al. Oct 2004 A1
20040200474 Lurie Oct 2004 A1
20040210281 Dzeng et al. Oct 2004 A1
20040211415 Lurie Oct 2004 A1
20040211416 Lurie Oct 2004 A1
20040211417 Lurie Oct 2004 A1
20040231664 Lurie et al. Nov 2004 A1
20040267325 Geheb et al. Dec 2004 A1
20050016534 Ost Jan 2005 A1
20050075531 Loeb et al. Apr 2005 A1
20050126567 Lurie Jun 2005 A1
20050165334 Lurie Jul 2005 A1
20050199237 Lurie Sep 2005 A1
20050217677 Lurie et al. Oct 2005 A1
20050267381 Benditt et al. Dec 2005 A1
20060089574 Paradis Apr 2006 A1
20060129191 Sullivan et al. Jun 2006 A1
20060270952 Freeman et al. Nov 2006 A1
20070017523 Be-Eri et al. Jan 2007 A1
20070021683 Benditt et al. Jan 2007 A1
20070060785 Freeman et al. Mar 2007 A1
20070199566 Be'eri Aug 2007 A1
20070221222 Lurie Sep 2007 A1
20070277826 Lurie Dec 2007 A1
20080039748 Palmer et al. Feb 2008 A1
20080047555 Lurie et al. Feb 2008 A1
20080092891 Cewers Apr 2008 A1
20080097258 Walker Apr 2008 A1
20080097385 Vinten-Johansen et al. Apr 2008 A1
20080108905 Lurie May 2008 A1
20080255482 Lurie Oct 2008 A1
20080257344 Lurie et al. Oct 2008 A1
20090020128 Metzger et al. Jan 2009 A1
20090062701 Yannopoulos et al. Mar 2009 A1
20090076573 Burnett et al. Mar 2009 A1
20090164000 Shirley Jun 2009 A1
20090277447 Voss et al. Nov 2009 A1
20090299156 Simpson et al. Dec 2009 A1
20100000535 Wickham et al. Jan 2010 A1
20100179442 Lurie Jul 2010 A1
20100319691 Lurie et al. Dec 2010 A1
20110056491 Rumph et al. Mar 2011 A1
20110098612 Lurie Apr 2011 A1
20110160782 Lurie et al. Jun 2011 A1
20110197887 Truschel et al. Aug 2011 A1
20110201979 Voss et al. Aug 2011 A1
20110297147 Lick et al. Dec 2011 A1
20120016279 Banville et al. Jan 2012 A1
20120203147 Lurie et al. Aug 2012 A1
20120302908 Hemnes et al. Nov 2012 A1
20120330199 Lurie et al. Dec 2012 A1
20120330200 Voss et al. Dec 2012 A1
20130118498 Robitaille et al. May 2013 A1
20130172768 Lehman Jul 2013 A1
20130231593 Yannopoulos et al. Sep 2013 A1
20130269701 Lurie Oct 2013 A1
20140005566 Homuth et al. Jan 2014 A1
20140048061 Yannopoulos et al. Feb 2014 A1
20150352302 Kuypers et al. Dec 2015 A1
Foreign Referenced Citations (46)
Number Date Country
1487792 Oct 1992 AU
60539 Nov 1994 AU
687942 May 1995 AU
668771 Aug 1963 CA
2077608 Mar 1993 CA
2214887 Sep 1996 CA
1183731 Jun 1998 CN
2453490 May 1975 DE
4308493 Sep 1994 DE
0029352 May 1981 EP
0139363 May 1985 EP
0245142 Nov 1987 EP
0367285 May 1990 EP
0411714 Feb 1991 EP
0509773 Oct 1992 EP
0560440 Sep 1993 EP
0623033 Nov 1994 EP
1344862 Jan 1974 GB
1465127 Feb 1977 GB
2117250 Oct 1983 GB
2139099 Nov 1984 GB
2005675 Jan 2005 JP
2006524543 Nov 2006 JP
2007504859 Mar 2007 JP
905518 May 1990 WO
9302439 Feb 1993 WO
9321982 Nov 1993 WO
9426229 Nov 1994 WO
9513108 May 1995 WO
9528193 Oct 1995 WO
9628215 Sep 1996 WO
9820938 May 1998 WO
9947197 Sep 1999 WO
9963926 Dec 1999 WO
0020061 Apr 2000 WO
0102049 Jan 2001 WO
0170092 Sep 2001 WO
0170332 Sep 2001 WO
02092169 Nov 2002 WO
2004096109 Nov 2004 WO
2006088373 Aug 2006 WO
2008147229 Dec 2008 WO
2010044034 Apr 2010 WO
2013064888 May 2013 WO
2013096495 Jun 2013 WO
2014026193 Feb 2014 WO
Non-Patent Literature Citations (54)
Entry
US 5,584,866 A, 12/1996, Kroll et al. (withdrawn)
Yannopoulos et al., “Controlled pauses at the initiation of sodium nitroprussdi e-enhanced cardiopulmonary resuscitation facilitate neurological and cardiac recovery after 15 minutes of untreated ventricular fibrillation,” Critical Care Medicine , 2012, pp. 1-8, vol. 40:5.
Zhao et. al., “Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning,” AJP Heart Circ Physiol, 2003, pp. H579-H588, vol. 285.
Zoll Autopulse Non-Invasive Cardiac Support Pump, obtained online on 715106 at http://www.zoll.com/product.aspx?id=84,1 page.
Advanced Circulatory Systems, Inc. (2005). Introducing ResQPOD® (#49-0324-000, 01) [Brochure). Roseville, MN: Advanced Circulatory Systems, Inc., 2 pages.
Advanced Circulatory Systems, Inc. (2006). ResQPOD® Circulatory Enhancer: Strengthening the Chain of Survival (#49-0336-000, 02). [Brochure). Roseville.MN: Advanced Circulatory Systems, Inc., 2 pages.
Advanced Circulatory Systems, Inc. (2006). ResQPOD® Circulatory Enhancer: Strengthening the Chain of Survival (#49-0336-000, 01) [Brochure). Roseville, MN: Advanced Circulatory Systems, Inc. 2 pages.
Advanced Circulatory Systems, Inc. (2009). ResQPOD® Perfusion on Demand: ResQPOD Impedance Threshold Device (#49-0324-001, 02) [Brochure). Roseville, MN: Advanced Circulatory Systems, Inc., 2 pages.
Advanced Circulatory Systems, Inc. (2010), ResQPOD Impedance Threshold Device: Strengthening the Chain of Survival (#49-0336000, 05) [Brochure], Roseville, MN: Advanced Circulatory Systems, Inc. 2 pages.
Advanced Circulatory Systems, Inc. (2010), ResQPOD Impedance Threshold Device: Strengthening the Chain of Survival (#49-0336000, 04) [Brochure], Roseville, MN: Advanced Circulatory Systems, Inc. 2 pages.
Advanced Circulatory Systems, Inc. (2010), ResQPOD Impedance Threshold Device 10.0: Strengthening the Chain of Survival (#49-0336000, 03) [Brochure], Roseville, MN: Advanced Circulatory Systems, Inc. 2 pages.
Advanced Circulatory Systems, Inc. (2010). ResQPOD® Perfusion on Demand: ResQPOD Impedance Threshold Device (#49-0324-001, 03) [Brochure). Roseville, MN: Advanced Circulatory Systems, Inc., 2 pages.
Advanced Circulatory Systems, Inc. (2011). ResQPOD® Perfusion on Demand: ResQPOD Impedance Threshold Device (#49-0324-001, 04) [Brochure). Roseville, MN: Advanced Circulatory Systems, Inc. 2 pages.
Advanced Circulatory Systems. Inc. (2011). ResQPOD® Perfusion on Demand: ResQPOD Impedance Threshold Device (#49-0324-001, 05) [Brochure). Roseville, MN: Advanced Circulatory Systems, Inc., 2 pages.
Advanced Circulatory Systems, Inc. (2011), ResQPOD ITD: Strengthening the Chain of Survival (#49-0336000, 06) [Brochure], Roseville, MN: Advanced Circulatory Systems, Inc. 2 pages.
Advanced Circulatory Systems, Inc. (Aug. 2011), Early Intervention is Life-Saving in Cardiac Arrest (#49-0864-000,01) [Brochure], Roseville, MN: Advanced Circulatory Systems, Inc. 2 pages.
Advanced Circulatory Systems, Inc. (Aug. 2011), Early Intervention is Life-Saving in Cardiac Arrest (#49-0864-000,02) [Brochure], Roseville, MN: Advanced Circulatory Systems, Inc. 2 pages.
Advanced Circulatory Systems, Inc. (Jan. 2012), Benefits of the ResQPOD Based Upon the ROC Primed Study (#49-0864-000,03) [Brochure], Roseville, MN: Advanced Circulatory Systems, Inc. 2 pages.
Advanced Circulatory Systems, Inc. (Mar. 2012), Benefits of the ResQPOD Based Upon the ROC Primed Study (#49-0864-000,04) [Brochure], Roseville, MN: Advanced Circulatory Systems, Inc. 2 pages.
Advanced Circulatory Systems, Inc. (2013), ResQPOD More than a Heartbeat (#49-0336-000,08) [Brochure], Roseville, MN: Advanced Circulatory Systems, Inc. 2 pages.
Advanced Circulatory Systems, Inc. (Jan. 2013), Emerging Data: The Resuscitation Outcomes Consortium (ROC) Primed Study on the Efficacy of the ITD (#49-0864-000,05) [Brochure], Roseville, MN: Advanced Circulatory Systems, Inc. 2 pages.
Advanced Circulatory Systems, Inc. (Jan. 2014), Emerging Data: The Resuscitation Outcomes Consortium (ROC) Primed Study on the Efficacy of the ITD (#49-0864-000,06) [Brochure], Roseville, MN: Advanced Circulatory Systems, Inc. 2 pages.
Ambu InternationalNS Directions for use of Ambu® CardioPump™ —Sep. 1992, 8 pages.
Aufderheide et al., “Hyperventilation-Induced Hypotension During Cardiopulmonary Resuscitation,” Circulation; 2004, pp. 1960-1965, vol. 109:16.
Aufderheide et al., “Standard cardiopulmonary resuscitation versus active compression-decompression cardiopulmonary resuscitation with augmentation of negative intrathoracic pressure for out-of-hospital cardiac arrest: A randomized trial”, 2011, Lancet, pp. 301-311, vol. 377.
Azim et al. “The use of bispectral index during a cardiopulmonary arrest: a potential predictor of cerebral perfusion,” Anaesthesia, 2004, pp. 610-612, vol. 59.
Babbs, “CPR Techniques that Combine Chest and Abdominal Compression and Decompression: Hemodynamic Insights from a Spreadsheet Model,” Circulation, 1999, pp. 2146-2152.
Christenson et al., “Abdominal Compressions During CPR: Hemodynamic Effects of Altering Timing and Force”, The Journal of Emergency Medicine, 1992, pp. 257-266, vol. 10, pp. 257-266.
Cohen et al., “Active compression-decompression resuscitation: A novel method of cardiopulmonary resuscitation,” American Heart Journal, pp. 1145-1150, vol. 124:5.
Cohen et al., “Active Compression-Decompression: A New Method of Cardiopulmonary Resuscitation,” 1992, JAMA, pp. 2916-2923, vol. 267:29.
Dupuis, “Ventilators—Theory and Clinical Application,” Jan. 1986, The C.V. Mosby Company, pp. 447-448.
Geddes et al., “Electrically Produced Artificial Ventilation,” Medical Instrumentation, 1988, pp. 263-271, vol. 22:5.
Geddes et al., “Optimum Stimulus Frequency for Contracting the Inspiratory Muscles with Chest-Surface Electrodes to Produce Artificial respiration,” Annals of Biomedical Engineering, 1990, pp. 103-108, vol. 18.
Geddes et al., “Inspiration Produced by Bilateral Electromagnetic, Cervical Phrenic Nerve Stimulation in Man,” IEEE Transactions on Biomedical Engineering, 1991, pp. 1047-1048, vol. 38:9.
Geddes, “Electroventilation—A Missed Opportunity?” Biomedical Instrumentation & Technology, 1998, pp. 401-414.
Glenn et al., “Diaphragm Pacing by Electrical Stimulation of the Phrenic Nerve,” Neurosurgery, 1985, pp. 974-984, vol. 17:6.
Glenn et al., “Twenty Years of Experience in Phrenic Nerve Stimulation to Pace the Diaphragm,” Nov./Dec. 1986, Part I, Pace 9, pp. 780-784.
Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiac Care, JAMA, 1992, pp. 2172-2177, vol. 268.
Johnson et al. “Time to throw away your stethoscope? Capnography: Evidence-based patient monitoring technology,” J. Radio. Nurs., 2011, pp. 25-34, vol. 30.
Jung et al., “Usefulness of the bispectral index during cardiopulmonary resuscitation,” Korean J Anesthesiol, 2013, pp. 69-72, vol. 64:1.
Kotze et al., “Diaphragm pacing in the treatment of ventilatory failure,” SAMT, 1995, pp. 223-224, vol. 68.
Laghi et al., “Comparison of Magnetic and Electrical Phrenic Nerve Stimulation in assessment of Diaphragmatic Contractility,” American Physiological Society, 1996, pp. 1731-1742.
Lindner et al., “Effects of Active Compression-Decompression Resuscitation on Myocardia land Cerebral Blood Flow in Pigs,” Circulation, 1993, pp. 1254-1263, vol. 88:3.
Lurie et al., “Regulated to Death: The Matter of Informed Consent for Human Experimentation in Emergency Resuscitation Research,” PACE, 1995, pp. 1443-1447, vol. 8.
Lurie et al., “Comparison of a 10-Breaths-Per-Minute Versus a 2-Breaths -Per-Minute Strategy During Cardiopulmonary Resuscitation in a Porcine Model of Cardiac Arrest,” Respiratory Care, 2008, pp. 862-870, vol. 53:7.
Michigan Instruments, Inc., Thumper 1007CC Continuous Compression Cardiopulmonary Resuscitation System, obtained online Jul. 15, 2006 at http://www.michiganinstruments.com/resus-thumper.htm, 1 page.
Mushin et al., “Automatic Ventilation of the Lungs—The Lewis-Leigh Inflating Valve,” 1969, Blackwell Scientific, Oxford, GB, p. 838.
Schultz et al., “Sodium nitroprusside enhanced cardiopulmonary resuscitation (SNPeCPR) improves vital organ perfusion pressures and carotid blood flow in a porcine model of cardiac arrest,” Resuscitation, 2012, pp. 374-377, vol. 83.
Segal et al., “Ischemic postconditioning at the initiation of cardiopulmonary resuscitation facilitates cardiac and cerebral recovery after prolonged untreated ventricular fibrillation,” Resuscitation, 2012, pp. 1-7.
Shapiro et al., “Neurosurgical Anesthesia and Intracranial Hypertension,” Anesthesia, 3rd Edition, 1990, Church Livingston, New York, Chapter 54, pp. 1737-1789.
Yannopoulos et al., “Intrathoracic Pressure Regulator During Continuous-Chest-Compression Advanced Cardiac Resuscitation Improves Vital Organ Perfusion Pressures in a Porcine Model of Cardiac Arrest”, Circulation, 2005, pp. 803-811.
Yannopoulos et al.,“Intrathoracic pressure regulation improves vital organ perfusion pressures in normovolemic and hypovolemic pigs,” Resuscitation, 2006, pp. 445-453, vol. 70.
Yannopoulos et al., “Intrathoracic Pressure Regulation Improves 24- Hour Survival in a Porcine Model of Hypovolemic Shock,” Anesthesia & Analgesia, ITPR and Survival in Hypovolemic Shock, 2007, pp. 157-162, vol. 104:1.
Yannopoulos et al., “Sodium nitroprusside enhanced cardiopulmonary resuscitation improves survival with good neurological function in a porcine model of prolonged cardiac arrest,” Critical Care Medicine, 2011, pp. 1-6, vol. 39:6.
Related Publications (1)
Number Date Country
20180206785 A1 Jul 2018 US
Provisional Applications (1)
Number Date Country
61829176 May 2013 US
Continuations (2)
Number Date Country
Parent 15420653 Jan 2017 US
Child 15927607 US
Parent 14292578 May 2014 US
Child 15420653 US